Genetic testing to find causes of paclitaxel nerve damage
Part of Cancer, Skin clinical trials.
This study uses genetic tests on blood DNA to look for differences that may explain why some people develop nerve pain (peripheral neuropathy) from paclitaxel used for breast cancer. It compares people who got significant neuropathy during treatment with people who did not get neuropathy after completing paclitaxel.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are in the study group for either European American or African American ancestry
- You have DNA samples available that the study can use
- You were treated with paclitaxel for breast cancer
- You developed peripheral neuropathy during paclitaxel treatment (severity level depends on your ancestry)
- You did NOT develop peripheral neuropathy after completing the full course of paclitaxel
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses DNA genetic testing to find DNA changes that might explain why some people develop heart failure (CHF) after breast cancer treatment with certain medicines. It may help researchers understand risk and improve care for future patients.
This study uses whole exome DNA testing to look for inherited genetic differences that may explain why some people develop very high blood pressure from bevacizumab during breast cancer treatment. It compares people who did vs. did not develop severe bevacizumab-related hypertension.
This study looks at cancer-related inherited gene changes using blood samples. It may help patients and doctors understand cancer risk and guide treatment planning, especially across different ethnic communities.
This study looks at whether certain markers in your blood can predict nerve damage from paclitaxel chemotherapy. If you join, researchers will monitor your nerve health during treatment to better understand and possibly prevent side effects.
This study aims to find a blood test that can predict which patients will develop nerve pain or numbness (peripheral neuropathy) from certain chemotherapy drugs. You may be eligible if you are about to start treatment with paclitaxel, docetaxel, or oxaliplatin for at least 9 weeks.
This study looks at whether a common chemotherapy drug called paclitaxel (Taxol) causes nerve damage (peripheral neuropathy) in people with advanced stomach cancer. The goal is to find out who is most likely to get this side effect, so doctors can better protect patients during treatment.
Hear when a new Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.